Johan Lundberg

Johan Lundberg

Professor/Överläkare
E-postadress: johan.lundberg@ki.se
Besöksadress: Akademiska Stråket 1, Bioclinicum, J4-14, 17176 Stockholm
Postadress: K8 Klinisk neurovetenskap, K8 CPF Lundberg, 171 77 Stockholm

Om mig

  • Johan Lundberg, leg. läkare, med. dr, är professor i psykiatri vid Institutionen för klinisk neurovetenskap, Karolinska Institutet, och överläkare vid Norra Stockholms psykiatri (SLSO). Han leder en forskargrupp inom molekylär hjärnavbildning och neuropsykofarmakologi.

    Forskningen utgår från en klinisk fråga som angrips från flera håll: vad förändras i hjärnan, och i patienternas liv, när ett psykiatriskt syndrom som depression behandlas framgångsrikt? För att besvara den kombinerar gruppen tre angreppssätt.

    Molekylär avbildning av behandlingsmekanismer. Med PET och MR studerar gruppen hur antidepressiva behandlingar verkar i den mänskliga hjärnan. En serie studier har pekat ut serotonin 1B-receptorn som en möjlig förändringspunkt efter behandling med SSRI, ketamin och elektrokonvulsiv behandling (ECT). Nyare arbeten undersöker synaptisk densitet och neuroplasticitet vid depression med SV2A-radioliganden [11C]UCB-J.

    Kliniska prövningar av nya behandlingar. Gruppen genomför randomiserade, placebokontrollerade prövningar av psilocybin vid egentlig depression. Bland dem finns PSIPET-studien, som kombinerar kliniska utfall med PET-avbildning och biomarkörer i likvor och blod; de kliniska huvudresultaten publicerades i JAMA Network Open 2026. Gruppen leder också multicenterstudien CAPSI, som gäller patienter med cancerrelaterad depression. Dessutom studerar gruppen metodfrågor i psykedelikaprövningar, bland annat utbildning av terapeuter och utfall i kontrollgrupper.

    Utfall i vanlig vård. Med svenska hälsodataregister och totalbefolkningsdata från Stockholmsregionen studerar gruppen hur depression och dess behandlingar utvecklas i rutinsjukvården. Hit hör utfall av ECT och rTMS, tillfrisknande och återfall, övergång från unipolär depression till bipolär sjukdom samt vårdutnyttjande.

    Alla tre angreppssätten vilar på metodologisk stringens. Gruppen utvecklar och validerar metoder för att kvantifiera PET-data, bland annat bayesiansk modellering och referensregionsmetoder.

    Johan Lundberg tog läkarexamen 1998 och disputerade 2006 vid Karolinska Institutet. Han blev specialist i psykiatri 2007, docent 2015 och professor 2025. Han är eller har varit huvud- eller bihandledare för 14 doktorander och har publicerat mer än 100 vetenskapligt granskade artiklar. Han är co-chair för ECNP Psychedelics Research Network (European College of Neuropsychopharmacology), medverkar i Socialstyrelsens nationella riktlinjer för depression och ångest och var med och grundade Svenska nationella kvalitetsregistret för ECT, där han sitter i styrgruppen.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Förbä ttrad förståelse och förebyggande av suicid vid depression genom integra tion av gene tisk och epidemiologisk data i Stockholm MDD-kohorten
    ALF Medicin
    1 januari 2026 - 31 december 2028
  • Sammanlänkande av synaptisk densitet och förändringar av aktivitet i hjärnans nätverk.
    Hjärnfonden
    1 juli 2025 - 31 december 2027
  • Swedish Research Council
    1 december 2024 - 30 november 2028
    The purpose of this study is to test the hypothesis of increased antidepressant efficacy of accelerated intermittent theta-burst stimulation (aiTBS) in depression through concomitant modulation of the N-methyl-D-aspartate receptor (NMDAR). The specific aim is to evaluate the effect of augmentation with the partial NMDAR agonist D-cycloserine during aiTBS for depressive symptoms in a placebo controlled randomized controlled trial. In this multicenter study we will recruit 90 patients, 18 years and older with an ongoing major depressive episode referred for clinical iTBS. Study participants will be randomized to receive either 100 mg D-cycloserine or placebo at each treatment day with aiTBS (6 sessions/day) in a double-blinded fashion during nine week-days. Primary outcome is change in depressive symptoms on the Montgomery–Åsberg Depression Rating Scale (MADRS) after the intervention. Secondary outcomes are change in Clinical Global Impression, as well as in weekly patient reported outcomes of depressive symptoms, and side-effects, including a four-week and six-month follow-up. We will also explore if the effects of D-cycloserine is more pronounced in patients with impaired neuroplasticity. If efficacy is demonstrated D-cycloserine augmented aiTBS could readily be implemented in clinical practice to decrease the disease burden of treatment resistant depression. Further, it may also serve as a long-awaited inpatient treatment alternative for rapid depressive symptom control.
  • Swedish Cancer Society
    1 januari 2024
    A third of those who get cancer also develop it Depression. Despite the special circumstances of these patients, with concomitant cancer treatment, reduced quality of life and often expected shortened lifespan related to the cancer itself, there is no specific antidepressant treatment introduced in care. A single dose of psilocybin has shown a rapid (within days) and long-term (months to years) antidepressant effect in several small studies in which different cancer groups included. There is still a lack of good studies to introduce the treatment in clinical practice. There is also a lack of knowledge about which patients benefit of this particular treatment. 100 patients with cancer and depression are randomized to treatment with pslicybin or placebo i four different regions in Sweden during 2024-2025. We are investigating the antidepressant effect as well side effects 6 weeks after treatment and after six months. All patients submit blood samples and undergoes EEG examination before and six weeks after the treatment. The 25 patients participating in The Stockholm region is also examined with three other more demanding methods, MEG, fMRI and PET, to be able to create a simple measure where we can predict which patients with the help of blood tests and EEG who benefit most from psliocybin even before treatment. All this information will be used to carry out a so-called phase three study of psilocybin in cancer-related depression, where we also can refine the prognostic tool, blood tests and EEG, to see which patients benefit the most the treatment. After that, this treatment, together with the prognosis tool, can be introduced in usual clinical care. We think it can happen in 2031.
  • Swedish Research Council
    1 januari 2023 - 31 december 2026
    Background: The age standardised rate of yearly new cancer cases is 190/100 000 globally, by WHO. 30-40% of these will develop depression. There is currently no specific antidepressant treatment regime implemented in the cancer population. This is in spite of the specific needs given by concurrent cancer treatments, limited quality of life from the cancer per se and the often limited life expectancy from a cancer disease. A single dose of psilocybin combined with 3 hours of psychological support has shown rapid (within days) and long term (months or years) antidepressant effect in several small studies in different cancer populations. Large, well designed RCTs are still lacking, as is response predictors for treatment guidance. I am PI of the first RCT of psilocybin treament of depression in Sweden, expected to end randomisation in june 2022. CAPSI: 100 patients with cancer and depression will be randomised to psilocybin or active placebo (2:1) at 4 different regions in Sweden during 2024-2025. Primary end point is depressive symptoms 6 weeks post dose and follw up is 6 months. All subjects will undergo EEG and blood sampling, a subsample (n=50) will also undergo MEG and fMRI, and 25 of them also PET, in order to develop a EEG proxy response signature. Together with markers in blood we will develop a predictor model for psilocybin treatment response. All data will be used to motivate a phase three study with the same PICO and further development of the response markers.
  • Swedish Research Council
    1 januari 2023 - 31 december 2026
    While the selective serotonin reuptake inhibitors (SSRIs) are first line of treatment of depression, 30% of patients do not respond adequately. Adding an atypical antipsychotic agent to the SSRI may lead to a marked response in these cases, this having become a recommended strategy. Antipsychotic drugs are, however, marred by serious side effects, such as motor impairment, apathy, and the metabolic syndrome. OSU6162 is a dopamine stabilizer developed by Nobel prize winner Arvid Carlsson which bears pharmacological similarities to atypical antipsychotics, but which, according to experimental and clinical studies (where it has been tested mainly for the treatment of fatigue), is more activating than these, and entirey devoid of their side effects. A network of clinicians in Gothenburg, Kungälv, Lund, Stockholm, and Uppsala will now perform a randomized, 5-center, placebo-controlled trial aiming to assess the efficacy and tolerability of OSU6162 as add-on (flexible dose
    6 weeks of treatment
    n=80 per group) in patients who have not responded to six weeks of treatment with an SSRI or a serotonin and noradrenaline reuptake inhibitor (SNRI). Mixed model statistics will be used to compare the groups with respect to the sum score for 6 core items of the Hamilton Depression Rating Scale at week 6. First patient first visit: Q1/2023
    last patient last visit: Q4/2025. Patient benefit: an effective and tolerable treatment for SSRI-resistant depression is an important unmet medical need.

Anställningar

  • Professor/Överläkare, Psykiatri, Klinisk neurovetenskap, Karolinska Institutet, 2025-
  • Adjungerad Professor, Klinisk neurovetenskap, Karolinska Institutet, 2022-2025

Examina och utbildning

  • Docent, Psykiatri, Karolinska Institutet, 2015
  • MEDICINE DOKTORSEXAMEN, Institutionen för klinisk neurovetenskap, Karolinska Institutet, 2006
  • Läkarexamen, Karolinska Institutet, 1998

Nyheter från KI

Kalenderhändelser från KI